· AIM:Tosystematicallyreviewthecurrentevidence based on the efficacy and cost of Ex-PRESS implantationandtrabeculectomy(Trab)foruncontrolled glaucoma.
.Consequently,itis essentialtocreateabetterandsaferoperation. TheEx-PRESSglaucomafiltrationimplantationwas developedasanalternativetoTrab.Itisasmall,stainless andnon-valvedflow-restrictingdevice.Implantationofthe Ex-PRESSshuntunderascleralflapissimilartothe traditionalTrab,whichcanavoidtheneedforaperipheral iridectomy.Thus,implantationoftheEx-PRESSmayreduce thelikelihoodofhyphemaandresultinlesspostoperative inflammation.Becauseofthefixed-diametertubesizeand relativestablefiltering volumeofEx-PRESS,the complicationsofhypotonycausedbyover-fluentfiltering maybeless.Therefore,theEx-PRESSshuntmayprovidea morereliablefilteringprocedureforglaucomasurgeons, especiallyforthosesurgeonsnewtotheprocedure,suchas ophthalmologyresidents.Consequently,theEx-PRESS glaucomafiltrationimplantationhasbeenusedsuccessfully inapproximately60000patientsworldwide [3] .However, giventhe limitedhealthcareresourcesavailable,itis importanttoknowwhethertheEx-PRESSishighly cost-effective. ThreestudiessofarhavecomparedthecostofEx-PRESS withthatofTrab [2, [4] [5] .Onestudy [2] foundthatthetwogroups exhibitedcomparableefficacyandsafety,whileEx-PRESS groupcostmorethanTrabgroup.However,theothertwo studies [4] [5] [9] [10] [11] [12] fromtwoidenticalclinicaltrials,wechosethelatest publicationforeachclinicaltrial [9] [10] .Toachievethecomplete data,wepooledtheresultsfromdifferentarticlesthat derivedfromanidenticalstudy,andweonlypulleddata from2articles,butdidnotincludetheminthepresent study [10] [11] .Therefore,only11studiesand2abstractsmetthe inclusioncriteriainthispaperreviewfrom2007to November2014.Figure1providedtheflowofsearchresults. Study Characteristics and Quality Thebasic characteristicsoftheincludedstudiesweredescribedin Table1.Tenstudieswereusedtoanalyzetheefficacyand safetyforEx-PRESSandTrab.Therefore,atotalof769eyes and2abstracts [4] [5] . Amongthe10includedstudies,therewere4randomized-controlledtrial(RCT)studies [9] [10] [13] [14] ,4retrospective studies [15] [16] [17] [18] ,and2prospectivestudies [19] [20] . [10, [13] [14] [15] [16] [18] [19] [20] , 8studies [9] [10] [13] [14] [15] [16] 18, 20] and3studies [9, [13] [14] toevaluatetheeffectof twosurgicalproceduresonIOP-loweringat6,12and24mo postoperativebysubgroupanalysis,respectively.Wefound thattherewasasimilarresultincomparisonwithEx-PRESS andTrabregardingIOPR%at1,2yaftersurgery( =0.50, 0.60,respectively).Nevertheless,statisticaldifferencewas foundat6mo( =0.03),whichshowedthatEx-PRESShad alowerIOPR%comparedwithTrab(detaileddatawere presentedinFigure2 =0.00%,respectively)(Table2). Sixstudies [9] [10] 13, [16] [17] [18] reportedtherelevantdataforcomplete successrate,whichwasdefinedthatIOPwascontrolled 逸5mmHgand 臆21mmHgor 逸5mmHgand 臆18mmHg withoutmedications.Analysisofthosedatashowedthatthe completesuccessratewasstatisticallysignificantlyhigherin Ex-PRESSgroupthanthatinTrabgroup(OR:1.59;95% CI:1.07-2.35; =0.02).Asensitivityanalysiswasperformed toevaluatetheeffectofexcludingthenon-randomized studies [16] [17] [18] ,andthestatisticalresultsdidnotchange(OR: 1.94;95%CI:1.05-3.59; =0.03)(Table3). Allstudies [9] [10] [13] [14] [15] [16] [17] [18] [19] [20] havereportedthequalifiedsuccessrate whichwasdefinedtheIOPwaswellcontrolled 逸5mmHg and 臆21mmHgor 逸5mmHgand 臆18mmHgwithor withoutmedications.Thesedatademonstratedthatthe qualifiedsuccess rateshowedstatisticallysignificant differencebetweenEx-PRESSandTrabgroups(OR:1.74; 95%CI:1.06-2.86; =0.03).Asensitivityanalysiswas performedtoexaminetheeffectofexcludingthenonrandomizedstudies [15] [16] [17] [18] [19] [20] ,wherebythestatisticalresultsdidnot change(OR:2.25;95%CI:1.07-4.73; =0.03)(Table3 [2] performedaneconomicanalysisof1-yearpostoperativecost andoveralltotalcostdifferenceoftheEx-PRESSdevice comparedwithTrab.Theresultshowednosignificant [21] .Thesignificanteconomicimplicationsofthe insertionofanEx-PRESSdeviceneedtobeconsideredif thisprocedureistosupersedeTrabasthestandardof practice.Infact,thecostassociatedwiththetwooperations includessurgeryitselfandtherelevantpostoperativecost, andthelatteriscalculatedbasedonthepooledcostof follow-upvisits,additionalprocedures,andmedication required [2] ,whichisassociatedwiththeefficacyandsafety. Thus,the efficacyandsafetyarebothtakeninto considerationsufficientlytowellanalyzethecostfortwo operations. Inthepresentsystematicreview,wealsofoundthatthe Ex-PRESScouldachievehighersuccessratethanTrab, includingbothcompleteandqualifiedsuccessrate,though theyachievedsimilarresultsinlowingIOPcomparableto thoseofTrabin differentdurations.Apublished Meta-analysis [22] showedthatthesuccessratewassimilarfor Ex-PRESSandTrab,whichdifferedfromourconclusion. Thereasonfortheconflictingresultsmaybebecausemore RCTswereincludedinourstudy,whichcanprovidemore sufficientandcompetentevidence.Meanwhile,withthe increasedapplicationofEx-PRESSandrichexperiencein surgeons,thesuccessratewillbeincreased.Consequently, highqualifiedsuccessratemeansdrugsavingsandless postoperativecostforglaucomapatients. Inassessingthecomplication,itwasnotedthatEx-PRESS hadasignificantlylowerfrequencyofhypotonyand hyphemathantraditionalTrab.Inthemeantime,patients withtheEx-PRESSinplacewerelesslikelytoexperience hypotony,whichmaybeduetoinherentflowregulationsof theP-50model's50 滋minternallumendiameter [9, 13, 16, 23] . Hypotonythatmayleadtovisionlossneedsextrahandleand thusresultsinmorepostoperativecost.Whereasthe Ex-PRESSproceduredidnotrequirethecreationofa peripheraliridectomyconductedinTrab,whichmay contributetolesslikelihoodofhyphema.Ex-PRESShad fewerratesofcomplications(includingmaculopathy, encapsulatedbleb,andchoroidaldetachment)thanTrab,but nosignificantdifferencewasfound. Regardingthecost-effectiveness,thepresentstudydeduces thatthepostoperativecostmightbegraduallyreducedwith highersuccessrate,savingsinIOP-loweringmedicationsand eyesurgeriesinEx-PRESSgroup.Guidelinesforthe adoptionandappropriateutilizationofnewtechnologies havepreviouslybeenpublishedbyLaupacis [24] .The decisiononwhethertoimplementanewtherapydependson notonlythelevelsofevidence(thequalityofthestudy),but alsothelikelihoodofthemagnitudeoftheincrementalcosts requiredtoachieveeachadditionalunitofbenefit.The suggestedgradesofrecommendationclassifytherapieson thebasisofthemagnitudeoftheirincrementalnetbenefits ofatechnology.Moreover,basedonthefindingswe obtained,theEx-PRESSismoreeffectivethanTrabbecause ofahighersuccessrateandlesscomplications.Sothe Ex-PRESSdevicewouldbeclassifiedasgradeBorCorDmoreeffectiveandmorecostlythanTrab [24] . Nevertheless,therewereseverallimitationsinthisreview. First,thestudiesincludedinthepresentstudyweremostly performedindevelopedcountries.Thereasonmaybethat thestudiesinvolvedinEx-PRESSdidnotbecarriedoutor publishedindevelopingcountrieswherethecosteffective surgeryisurgentlyneeded.Importantly,themajorglobal burdenofglaucomastillremainsindevelopingcountries [1] . Therefore,relevantstudiesshouldbedoneindeveloping countries.Second,wecannotfullyexcludepublicationbias becausewedidnotgainaccesstounpublishedresultsand moredetailsoftheabstract.Third,therewasalarge disparityinstudyqualitybecauseallstudiesincludedwere toovariedinthetypesofclinicalstudies,surgeontypes, differentgenerationsoftheEx-PRESSdevicesused,typesof surgeryperformed,resultingintheconclusionsfromthis Meta-analysiswerenotrobust.Fourth,despiteanextensive systematicsearchoftheliterature,only3studiesassessedthe costofEx-PRESSversusTrab,the3studieswereperformed atdifferenttimes,differentlocationsanddifferentmedical equipmentprices,whichcouldreducetheconfidencelevelof theoutcomes.Last,datafromtrialsincludedinthis Meta-analysiswerecomparedatdifferentdurations,andwe hadnochoicebuttoselectthefollow-upend-pointto analyzemajoroutcomes. Toourknowledge,thelong-termresultsarestilllackingin thepresentMeta-analysispaper.Thetwostudiesperformed bydeJong [4] [5] ,whichhaveameanfollow-upperiodof 5y,showedthatthepostoperativecostsforEx-PRESSwas lessthanTrab.Withtheincreaseinavailabilityofmore studiesaboutthecostoftheEx-PRESS,itcanpotentially improveourstudy.Leavingthelimitationsaside,our findingsimpliedthattheEx-PRESScouldachievehigher successrateandlesscomplicationthanTrabintherelative short-termbasedontheresultsofrelatedstudieswithpooled samples,thoughitmightcostmuchmorethanTrabbecause ofsurgerydevice.Inthelongrun,thecost-effectivenessof theEx-PRESSwilldecreaseduetosavingsineyesurgeries ( needlingandcataractsurgery)andeyedrop medicationsduringthefollow-up [4] . Inconclusion,ourstudyindicatesthattheEx-PRESScould achievehighersuccessrateandfewercomplications( hypotony andhyphema)comparedwithTrabinthe short-term.Meanwhile,itisconfirmedthatEx-PRESShada lowerpostoperativecostthanTrabat5-yearwhenreferredto cost-effectiveness.Nevertheless,theresultsshouldbe consideredwithcautionsbecauseofthelimitation( languagelimitation,publicationbias,differenceinstudy qualityanddifferentdurations).Despitethelimitations,we believethattheresultsofthecurrentMeta-analysisstudyare clinicallyusefulforglaucomatreatment.Todrawan accurateconclusion,moreRCTswithlargersamplesizesor systematicstudiesareurgentlyneededtobetterevaluatethe long-termbenefitsandcost-effectivenessbothforEx-PRESS andTrab.AlthoughtheEx-PRESSshuntis gaining popularity,therewasnocompleteconsistencewiththetype ofglaucomafortheuseoftheEx-PRESSimplantation,and reportsconcerningtherelativeefficacyandsafetyof Ex-PRESSandTrabarecontroversial.Theimplantationof Ex-PRESSshuntpossessesamarkedlyhighercostandmight beamajorlimitationinitsadoptionintoclinicalpractice, especiallyindevelopingcountries.Inviewofthispoint,itis necessarytoinformtheglaucomapatientsaboutthe cost-effectivenessandvoluntarychoiceoftheEx-PRESS. Nevertheless,furtherstudiesshouldbedonetoevaluatecosteffectivenesstoallowoptimalchoiceofglaucomasurgery.
